Slides
Page 1
SOPHiA GENETICS Company Overview August 2026
Page 2
© SOPHiA GENETICS 2026 Cautionary notices 2 This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this presentation. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this presentation to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Other material information This presentation does not contain all material information about the Company and its subsidiaries. No representations or warranties (expressed or implied) are made regarding the completeness of the information contained in this presentation. Refer to our Securities and Exchange Commission filings for additional information about us. Market and industry data This presentation contains industry, market and competitive position data that are based on general and industry publications, surveys and studies conducted by third parties, some of which may not be publicly available, and our own internal estimates and research. Third-party publications, surveys and studies generally state that they have obtained information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. While we are not aware of any misstatements regarding the industry, market and competitive position data presented herein, these data involve a number of assumptions and limitations and contain projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty. Research use only SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information included in this presentation is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. Non-IFRS measures This presentation contains certain “non-IFRS financial measures.” Reconciliations to the most directly comparable financial measures calculated and presented in accordance with IFRS are provided at the end of this presentation. These non-IFRS financial measures do not have standardized meanings under IFRS and may not be comparable to IFRS measures or ratios and may not be comparable to similarly titled non-IFRS financial measures reported by other companies, including those within our industry. Management believes that these measures are commonly reported by companies and widely used by investors as an indicator of a company's operating performance. These non-IFRS financial measures should be considered only as a supplement to, and not as a superior measure to, measures prepared in accordance with IFRS.
Page 3
© SOPHiA GENETICS 2026 Building the Intelligence Layer for Precision Medicine 3 Healthcare generates more data than most other industries. Yet decisions are still made under uncertainty. SOPHiA DDMTM is the intelligence layer that turns healthcare data into actionable insights. Our AI-native Platform doesn’t just process biology, it understands. At SOPHiA, we’re building a collective intelligence to transform patient care. Actionable Insights AI-native Platform Multimodal Health Data
Page 4
© SOPHiA GENETICS 2026 44 Application menu Platform interface AI Factories Data warehouse 4 391,000+ Patients analyzed in 2025 FIRST PRINCIPLES SOPHiA DDMTM – the AI Platform for Precision Medicine 115,000 Patients analyzed in Q2 26 $500M+ invested since inception AI
Page 5
© SOPHiA GENETICS 2026 How SOPHiA DDMTM is Used Every Day 5 Business model =xAnalysis volume • 391,000+ analyses in 2025 • Volume is driven by customer lands and application expands Average price per analysis • Price per analysis ranges from $100 - $500 per analysis, based on the sophistication of application Revenue • Genomics business made up >90% of total annual revenue in 2025 Sequencing Raw genomic data Data analytics by SOPHiA DDMTM SOPHiA CUSTOMERS TYPICAL GENOMICS WOR KFL OW Blood or tissue sample prep Patient is suspected of a disease BETTER OUTCOMES A C T G A C T G A A C T G A C T G A A C T G A C T G A A C T G A C T G A A C T G A C T G A A C T G A C T G A A C T G A C T G A A C T G A C T G A A C T G A C T G A A C T G A C T G A A C T G A C T G A A C T G A C T G A A C T G A C T G A A C T G A C T G A A C T G A C T G A
Page 6
© SOPHiA GENETICS 2026 SOPHiA DDMTM Connects One of the Largest Data Networks in Healthcare 6 Network inputs • Real-time, real-word data stream from over 391,000 patients per year • Intelligence from the brightest minds in healthcare, including 15 of the top 20 global cancer centers 1 Network outputs • Actionable insights to inform diagnosis & treatment • AI that constantly learns from data & collective intelligence being generated by the Platform 1,000+ Connected institutions 75 Countries across the globe Real-time, real -world data stream from 391,000+ patients per year (1) According to Newsweek’s 2026 World’s Specialized Oncology Hospitals list
Page 7
© SOPHiA GENETICS 2026 Why Customers Choose SOPHiA DDMTM 7 Note: The benefits described above are illustrative and may vary depending on specific use cases and customer circumstances. Results are not guaranteed and may not be representative of all customer experiences. Past outcomes do not guarantee future performance, and individual results may differ materially; Customers liste d indicate partnerships, existing, or priori engagements with these institutions. Accuracy reflects analytical concordance with a reference method under defined validation conditions for specified variant ty pes and regions and describes aggregate —not individual—performance.
Page 8
© SOPHiA GENETICS 2026 Substantial Volume and Data Growth Analysis volume by application type from 2015 – 2025 Data processed by SOPHiA DDM TM from 2021 to 2025 Analysis volume in 000s Volume growth is being driven by sophisticated new applications such as Liquid Biopsy Data compute is increasing materially, driven by volume and data complexity +40%
Page 9
© SOPHiA GENETICS 2026 Strong, Multi-Year Revenue and Volume Growth 9 2020 2021 2022 2023 2024 2025 $77.3M Revenue, 2020 – 2025 $28.4M $40.5M $47.6M $62.4M $65.2M 2020 2021 2022 2023 2024 2025 Analysis volume, 2020 – 2025 391K 163K 210K 246K 312K 352K 22% CAGR since 2020 One of the most widely used AI Platforms in healthcare
Page 10
© SOPHiA GENETICS 2026 SOPHiA’s Growth Algorithm 10 0 10 20 30 40 50 60 2021 2022 2023 2024 Illustrative depiction of SOPHiA GENETICS’ Growth Model1 Growth lever BioPharma Leveraging data, network, and Ai to serve BioPharma • Signed a new, multi-year agreement with AstraZeneca to launch two companion diagnostic (CDx) programs: (1) a decentralized Solid Tumor CDx, and (2) a HemOnc test for patients with blood cancer Recent updates as of Q2 Earnings on August 4, 2026 Land Signing new customers to the Platform • Signed 24 new customers in Q2 2026 and 124 new customers in FY 2025 • Continued to expand ACVs for new customers signings YoY 2 • Continued to sign premier healthcare institutions across the globe Expand Existing customers adding new applications • Performed a record 115,000 analyses in Q2 2026, up 22% year -over-year • Reached Net Dollar Retention of 117% in Q2 2026, up 1,000bps YoY • Signed several new expands across geographies in Q2 2026 Organic Precision medicine testing rates are increasing worldwide • DeciBio forecasts an NGS industry CAGR of ~7% from 2025 to 2026 3 • New sequencers (e.g., Roche, Element) set to expand NGS globally • TD Cowen estimates U.S. in-house blood testing will grow 7x by 2029 4 Recurring Recurring business model based on patient volumes • Annualized revenue churn was <1% in Q2 2026 • 542 core genomic customers currently use the Platform, up 52 YoY • Current customers include 7 of the top 10 cancer centers globally 5 (1) Illustrative example of the contribution to total annual revenue growth from each area. (2) ACV stands for Average Contrac t Value. (3) DeciBio’s 2025 NGS Manufacturer Market Size, Growth and Trends (2022 -2028). (4) TD Cowen CGP Survey, February 2026. (5) According to Newsweek’s 2026 World’s Specialized Oncology Hospitals list
Page 11
© SOPHiA GENETICS 2026 Land and Expand Growth Engine 11 Analysis volume by customer cohort, 2015 – 2025, ’000s Customers consistently expand usage over time, growing at a 34% CAGR since 2015 Cohort 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 CAGR Expansion multiple 2015 cohort 19K 32K 42K 49K 52K 46K 51K 54K 64K 67K 71K 14% 3.7x 2016 cohort - 12K 23K 28K 43K 36K 41K 41K 44K 38K 41K 14% 3.4x 2017 cohort - - 15K 31K 38K 38K 45K 49K 60K 67K 77K 23% 5.1x 2018 cohort - - - 11K 23K 24K 32K 35K 38K 41K 48K 23% 4.2x 2019 cohort - - - - 11K 14K 23K 26K 25K 28K 32K 19% 2.9x 2020 cohort - - - - - 5K 15K 15K 21K 25K 23K 34% 4.4x 2021 cohort - - - - - - 40K 34K 24K 25K 28K -9% 0.7x 2022 cohort - - - - - - - 11K 29K 30K 21K 24% 1.9x 2023 cohort - - - - - - - - 14K 26K 27K 40% 2.0x 2024 cohort - - - - - - - - - 7K 16K 129% 2.3x Total 19K 45K 80K 119K 167K 164K 246K 265K 319K 354K 383K 34% ExpandLand <1% ↓ Annualized revenue churn 2.3 ↑ Apps per customer in 2025 50% ↑ Customers using 2+ apps 30% ↑ Customers using 3+ apps 67 Net Promoter Score 124 ↑ New customers signed in FY 2025 24 ↑ New customers signed in Q2 2026 64% ↑ YoY revenue growth in the U.S. in Q2 2026 80% ↑ YoY revenue growth in Liquid Biopsy in Q2 2026 Note: The analysis volumes presented by cohort and reporting year include only Core Genomics Customers and exclude non -recurring, evaluation, research, and other one -time customer activity. Accordingly, these volumes do not reconcile to total analysis volumes reported in our MD&A and other public filings.
Page 12
© SOPHiA GENETICS 2026 2026 Growth Drivers 12 • U.S. market is relatively underpenetrated by SOPHiA • U.S. revenue volume grew 64% and U.S. analysis volume grew 60% YoY in Q2 2026 • Signed a strategic collaboration with Children’s Hospital of Philadelphia in Q2 2026 • Completed new customer go-lives for multiple large U.S. health systems in Q2 2026 • Signed over 100 customers to the new Liquid Biopsy and Solid Tumor apps MSK-ACCESS® & MSK-IMPACT® powered with SOPHiA DDMTM • Delivered 80% YoY revenue growth in Liquid Biopsy in Q2 2026 , as customers implement the application and begin to ramp usage • Continued to sign major new customers across geographies in Q2 2026 • Signed a new, multi-year agreement with with AstraZeneca (“AZ”) in to launch two companion diagnostic programs: (1) a decentralized Solid Tumor CDx, and (2) a HemOnc test for patients with blood cancer in Q2 2026 • Delivered strong growth from BioPharma partners in Q2 2026 as recently signed projects with AZ, Kartos, and others begin generating revenue Continue Strong Growth in the U.S. Market Land and Expand with New Applications in Liquid Biopsy and Solid Tumor Leverage the data and Ai from SOPHiA’s network to serve BioPharma
Page 13
© SOPHiA GENETICS 2026 FY 2025 highlights Figures as of Dec 31, 2025 Q2 2026 highlights Delivering Value to Patients and Shareholders 13 ~$40B+ market opportunity1 $500M+ invested in our AI since inception 2,700+ scientific publications +124 new customers signed in 20252 67 NPS score for SOPHiA DDMTM 27% adjusted EBITDA loss improvement in Q2 20264 19% Revenue growth in FY 2025 115% Net Dollar Retention in 2025 391K+ analysis volume in FY 2025 <1% annualized revenue churn 22% analysis volume growth in Q2 20263 (1) Includes our estimated addressable market for 2025. These estimates are primarily based on epidemiological data, includi ng incidence and prevalence estimates of addressable populations for each application, as well as a range of price assumptions for our products taking into account differences in panel sizes. (2) Core genomics custo mers. (3) Year-over-year growth comparing to the prior year period. (4) Adjusted EBITDA loss was $8.8 million in Q2 2026, compared to $12.0 million in Q2 2025 . (6) Cash and cash equivalents as of June 30, 2026. including the $57.5M raised in gross proceeds at the end of Q2 2026 through an oversubscribed public offering. Market leading technology 993 Customers across 75 countries AI native since founding $107.7M cash balance as of June 30, 20266 542 core genomic customers as of Q2 2026 +24 new customers signed in Q2 20262 27% revenue growth in Q2 2026 115K analysis volume in Q2 2026 $57.5M in gross proceeds raised in Q2 2026
Page 14
Financial Appendix
Page 15
© SOPHiA GENETICS 2026 Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin 2025 2026 (Amounts in USD Thousands) Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY IFRS Revenue $17,779 $18,323 $19,462 $21,707 $77,271 $21,688 $23,310 — — — Gross Profit $12,208 $12,270 $12,907 $14,692 $52,077 $14,749 $15,061 — — — Gross Margin 68.7% 67.0% 66.3% 67.7% 67.4% 68.0% 64.6% — — — Amortization of Capitalized Research & Development Expenses (1) 1,241 1,357 1,329 1,339 5,266 1,602 1,757 — — — Adjusted Gross Profit $13,449 $13,627 $14,236 $16,031 $57,343 $16,351 $16,818 — — — Adjusted Gross Margin 75.7% 74.4% 73.1% 73.9% 74.2% 75.4% 72.1% — — — 2025 2025 (Amounts in USD Thousands) Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY IFRS Revenue $17,779 $18,323 $19,462 $21,707 $77,271 $21,688 $23,310 — — — Operating Profit / (Loss) ($16,036) ($18,492) ($17,862) ($18,516) ($70,906) ($17,283) ($20,053) — — — Operating Margin (90.2%) (100.9%) (91.8%) (85.3%) (91.8%) (90.2%) (86.0%) — — — Amortization (1) (3) 1,312 1,428 1,402 1,411 5,553 1,672 1,827 — — — Share-Based Compensation Expense (2) 3,835 4,356 4,146 3,868 16,205 3,313 4,492 — — — Social charges related to share-based compensation (7) 355 (360) 1,317 (553) 759 1,068 1,240 — — — Non-Cash Pension Expense (4) 86 89 87 85 347 91 72 — — — Transaction Costs (5) — — 445 450 895 168 123 — — — Litigation Expenses (6) — — 605 1,825 2,430 689 1,130 — — — Notes to the Reconciliation of IFRS to Adjusted Financial Measures Tables (1) Amortiza tion of ca pitalized research and developme nt expe nses consists of software developme nt costs amortized using the stra ight-line method over an estima ted life of five ye ars. These expe nses do not have a ca sh impact but remain a recurring expe nse generated over the course of our research and developme nt initiatives. (2) Share-based compensation expe nse represents the cost of equity awards issue d to our directors, officers, and employees. The fair va lue of awards is compute d at the time the award is granted and is recognized over the ve sting period of the award by a charge to the income statement and a corresponding incre ase in other reserves within equity. These expe nses do not have a ca sh impact but remain a recurring expe nse for our business and represent an importa nt part of our overall compensation stra teg y. (3) Amortiza tion of intangible assets consists of costs rela ted to intangible assets amortized over the course of the ir useful lives. These expe nses do not have a ca sh impact, but we could continue to generate such expe nses through future ca pital investments. (4) Non-ca sh pension expe nse consists of the amount recognized in excess of actual contributions made to our defined pension plans to match actuarial expenses ca lculated for IF RS purposes. The differe nce represents a non-ca sh expense but remains a recurring expe nse for our business as we continue to make contributions to our plans for the foreseeable future. (5) Tra nsaction costs consists of expe nses incurred in connection with the Company’s shelf registration statement and the ATM program. (6) Litigation expe nses consists of expe nses rela ted to the company's defense of lawsuits file d by Guardant Health. (7) Social charg es related to share-based compensation consist of payroll taxes and other social charges on sha re-based compensa tion aw ards. These expenses have bee n, and will continue to be for the foreseeable future, a recurring expense in the company’s business.
Page 16
© SOPHiA GENETICS 2026 Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth (Amounts in USD Thousands) Q2 2025 Q2 2026 Y-o-Y Growth IFRS Revenue $18,323 $23,310 27% Current Period Constant Currency Impact (1) — (454) Constant Currency Revenue $18,323 $22,856 25% Presentation of Constant Currency Revenue (1) SOPHiA GENETICS operates internationally, and its revenues are generated primarily in the U.S. dollar, the euro and Swiss franc and, to a lesser extent, British pound, Australian dollar, Brazilian real, Turkish lira and Canadian dollar depending on the company’s customers’ geographic locations. Changes in revenue include the impact of changes in foreign currency exchange rates. We present the non-IFRS financial measure “constant currency revenue” (or similar terms such as constant currency revenue growth) to show changes in revenue without giving effect to period-to-period currency fluctuations. Under IFRS, revenues received in local (non-U.S. dollar) currencies are translated into U.S. dollars at the average monthly exchange rate for the month in which the transaction occurred. When the company uses the term “constant currency”, it means that it has translated local currency revenues for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenues into U.S. dollars that we used to translate local currency revenues for the comparable reporting period of the prior year. The company then calculates the difference between the IFRS revenue and the constant currency revenue to yield the “constant currency impact” for the current period. The company’s management and board of directors use constant currency revenue growth to evaluate growth and generate future operating plans. The exclusion of the impact of exchange rate fluctuations provides comparability across reporting periods and reflects the effects of customer acquisition efforts and land-and-expand strategy. Accordingly, it believes that this non-IFRS measure provides useful information to investors and others in understanding and evaluating revenue growth in the same manner as the management and board of directors. However, this non-IFRS measure has limitations, particularly as the exchange rate effects that are eliminated could constitute a significant element of its revenue and could significantly impact performance and prospects. Because of these limitations, you should consider this non-IFRS measure alongside other financial performance measures, including revenue and revenue growth presented in accordance with IFRS and other IFRS results. The table below provides the reconciliation of the most comparable IFRS growth measures to the non-IFRS growth measures for the current period.
Page 17
© SOPHiA GENETICS 2026 Reconciliation of IFRS Net Loss to Adjusted EBITDA (Amounts in USD Thousands) Q2 2025 Q2 2026 IFRS loss for the period ($22,414) ($22,356) Exclude the impact of: Depreciation $942 $1,080 Amortization (1) (3) $1,428 $1,827 Interest income ($419) ($231) Interest expense $559 $1,620 Fair value adjustments on warrant obligations ($58) $317 Foreign exchange gains (losses), net $3,078 $519 Income tax expense $762 $78 Share-based compensation expense (2) $4,356 $4,492 Social charges related to share-based compensation (7) ($360) $1,240 Non-cash pension expense (4) $89 $72 Transaction costs (5) — $123 Litigation expenses (6) — $1,130 Restructuring costs (8) — $1,255 Adjusted EBITDA ($12,037) ($8,834) Notes to the Recon ciliation of IFRS to Adjusted Financial Measu res Tables (1) Amortization of capitalized resear ch an d development expenses consists of software development costs amortized using the straight-lin e method over an estimated life of five years. These expenses do not have a cash impact but remain a recurring expense gener ated over the course of our resear ch an d development initiatives. (2) Share-based comp ensatio n expense represen t s the cost of equ ity awar ds issued to our directors, officers, an d employees. The fair value of awar ds is comp u t ed at the time the awar d is granted an d is recognized over the vest ing period of the awar d by a charge to the income stat ement an d a correspo nding increase in other reserves within equ ity. These expenses do not have a cash impact but remain a recurring expense fo r our business an d represen t an important part of our overall comp ensatio n strategy. (3) Amortization of intangible assets consists of costs relat ed to intangible assets amortized over the course of their useful lives. These expenses do not have a cash impact , but we could continue to gener ate such expenses through fu t u r e capital investments. (4) Non-cash pen sion expense consists of the amount recognized in excess of actual contribution s made to our defined pen sion plans to match actuarial expenses calculated fo r IFRS purposes. The difference represen t s a non-cash expense but remains a recurring expense fo r our business as we continue to make contribution s to our plans fo r the fo r eseeable fu t u r e. (5) Transaction costs consists of expenses incurred in connect ion with the Company’s shelf registration stat ement an d the ATM program. (6) Litigation expenses consists of expenses relat ed to the comp any's defense of lawsuits filed by Gu ardan t Health. (7) Social charges related to share-based compensation consist of payroll t axes and other social charges on share-based compensation awar ds. These expenses h ave been, and will contin ue to be for the foreseeable future, a r ecurrin g expense in t h e company’s business. (8) Restructuring costs consists of c o mpensation paid to employees during their garden leave perio d, sever ance, and any other amounts legally owed to the emplo yees resu lting from their terminat ion as part of a planned wo r kforce reduction. Additionally, it includes legal fees incurred as part of the restructuring pro c ess.